Background: The liver microenvironment plays a key role in liver fibrosis and carcinogenesis. This study aimed to fill the gap in knowledge on the interaction between hepatic stellate cells and endothelial progenitor cells with biomarkers of liver fibrosis and/or carcinogenesis, including Col1A1, TGF-β, and tenascin-C.
Methods: CD34+ stem cells were isolated from umbilical-cord-blood mononuclear cells. 2D and 3D co-culture of CD34+ UCB SCs and LX2 was performed. The cells were incubated in a CO2 incubator for three days. Morphological observation, qRT-PCR of TGF-β1 and COL1A1, and immunocytochemistry of tenascin-C were performed.
Results: CD34+ UCB SCs were viable in the 2D and 3D co-culture for 24 h. 3D co-culture of CD34+ UCB SCs and LX2 inhibited in vitro liver fibrosis by lowering Col 1A1 expression as compared to control. We observed lower TGF-β expression in 3D co-culture on days 1 and 2 followed by higher expression of TGF-β on day 3. 2D co-culture of CD34+ UCB SCs and LX2 showed a different level of COL1A1 and TGF- β expression compared with 3D co-culture. Spheroids from 2D co-culture of CD34+ UCB SCs and LX-2 showed immunoreactivity against tenascin-C.
Conclusion: Interaction between LX-2 and CD34+ UCB SCs in 3D co-culture inhibits in vitro liver fibrosis. The viability of CD34+ UCB SCs is essential for attenuation of TGF-β signaling in LX-2.
1. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250–61.
2. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2017;114:1123–8.
3. Gianelli G, Villa E, Lahn M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 2014;74:1890–4.
4. Antarianto RD, Septiana WL, Jusuf AA, Barasila AC, Pawitan JA, Fasha I. Comparison of 2D and 3D co-culture with hanging drop method to produce a more clinically relevant microenvironment. eJKI. 2017;5:121–6.
5. Caicedo-Carvajal CE, Liu Q, Goy A, Pecora A, Suh KS. Three-dimensional cell culture models for biomarker discoveries and cancer research. Transl Med. 2012;S1:005.
6. Breslin S, O’Driscoll L. Three-dimensional cell culture: The missing link in drug discovery. Drug Discov Today. 2013;18:240–9.
7. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut. 2005;54:142–51.
8. Weiskirchen R, Weimer J, Meurer SK, Kron A, Seipel B, Vater I, et al. Genetic characteristics of the human hepatic stellate cell line LX-2. PLoS One. 2013;8:e75692.
9. Lin N, Chen Z, Lu Y, Li Y, Hu K, Xu R. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol Res. 2015;45:326–36.
10. Yin Z, Dong C, Jiang K, Xu Z, Li R, Guo K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 2019;12:101–9.
11. Li Z, Wu W, Zhao C, Zhao C, Zhang X, Yang Z, et al. CCN1/Cyr61 enhances the function of hepatic stellate cells in promoting the progression of hepatocellular carcinoma. Int J Mol. Med. 2018; 41:1518–28.
12. Zekri ARN, Salama H, Medhat E, Musa S, Abdel-Halem H, Ahmed OS, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. J Stem Cell Res Ther. 2015;6:118.
13. Meiliana A, Wijaya A. Application of umbilical cord Stem cells in regenerative medicine. Indones Biomed J. 2014;6:115–22.
14. Abdel Aziz MT, EL Asmar MF, Mostafa S, Salama H, Atta HM, Mahfouz S, et al. Reversal of hepatic fibrosis by human CD34+ stem/progenitor cell transplantation in rats. Int J Stem Cells. 2010;3:161–74.
15. Ilic D, Miere C, Lazic E. Umbilical cord blood stem cells: Clinical trials in non-hematological disorders. Br Med Bull. 2012;102:43–57.
16. Liu Z, Chen M, Zhao R, Huang Y, Liu F, Li B, et al. CAF-induced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma. Acta Biochim Biophys Sin. 2020;52:18–25.
17. Trautwein C, Friedman SL, Schupan D, Pinzani M. Hepatic fibrosis: from concept to treatment. J Hepatol. 2015;62:S15–S24.
18. Soura S, Vives J. Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood. Metabolism. 2019;95:102–4.
19. El Fiky BA, Elkhatib GZ, Eldahsan T. Hepatoprotective effects of umbilical cord blood stem cells against liver fibrosis in vivo. AAMJ. 2015;13:152–9.
20. Mata MF, Hernandez D, Rologi E, Grandolfo D, Hassan E, Hua P, et al. A modified CD34+ hematopoietic stem and progenitor cell isolation strategy from cryopreserved human umbilical cord blood. Transfusion. 2019;59:3560–9.
21. Roura S, Poujal JM, Gálvez-montón C, Bayes-Genis A. The role and potential of umbilical cord blood in an era of new therapies: A review. Stem Cell Res Ther. 2015;6:123.
22. Gabr H, Zayed R, El-zayat AR. Comparison between different cord blood stem cell populations in efficiency of transdifferentiation into hepatic lineage. Ann Intl Interdisciplin Conf. 2013;1:762–9.
23. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA. 2012;109:9448–53.
24. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep. 2013;1:209–14.
25. Mallat A, Lotersztajn S. Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?. J Hepatol. 2013;59:383–6.
26. Dong L, Pu Y, Chen X, Qi X, Zhang L, Xu L, et al. hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. Stem Cell Res Ther. 2020;11:21.
27. Yang J, Li C, Zhang L, Wang X. Extracellular vesicles as carriers of non coding RNA in liver diseases. Front Pharmacol. 2018;19:415.
28. Chen L, Brenner DA, Kisseleva T. Combatting fibrosis: exosome-based therapies in the regression of liver fibrosis. Hepatol Commun. 2019;3:180–92.
29. Sane MS, Tang H, Misra N, Pu X, Malara S, Jones CD, et al. Characterization of an umbilical cord blood sourced product suitable for allogeneic applications. Regen Med. 2019;14:769–89.
30. Zhang L-T, Fang X-Q, Chen Q-F, Chen H, Xiao P, Peng X-B, et al. Bone marrow-derived mesenchymal stem cells inhibit the proliferation of hepatic stellate cells by inhibiting the transforming growth factor β pathway. Mol Med Rep. 2015;2:7227–32.
31. Jang YO, Jun BG, Baik SK, Kim MY, Kwon SO. Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol. 2015;21:141–9.
32. Nakamura T, Koga H, Iwamoto H, Tsutsumi V, Imamura Y, Naitou M, et al. Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis. Mol Ther Methods Clin Dev. 2016;3:16025.
33. Sayyed HG, Osama A, Idriss NK, Sabry D, Abdelrhim AS, Bakry R. Comparison of the therapeutic effectiveness of human CD34 + and rat bone marrow mesenchymal stem cells on improvement of experimental liver fibrosis in Wistar rats. Int J Physiol Pathophysiol Pharmacol. 2016;8:128–39.
34. Yin Z, Jiang K, Li R, Dong C, Wang L. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. Mol Cancer. 2018;17:178.
35. Chen R, Dong Y, Xie X, Chen J, Gao D, Liu Y, Ren Z, Cui J. Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. Int J Clin Exp Pathol. 2014;7:2527–35.
36. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68:3175–99.
37. Ma J-C, Huang X, Shen Y-W, Zheng C, Su Q-H, Xu J-K, Zhao J. Tenascin-C promotes migration of hepatic stellate cells and production of type I collagen. Biosci Biotechnol Biochem. 2016;80:1470–7.
Septiana WL, Antarianto RD, Louisa M, Jusuf AA, Barasila AC, Pawitan JA, et al. CD34+ UCB stem cells attenuate TGF-β signaling and inhibit liver fibrosis: A new avenue for liver cirrhosis-carcinogenesis prevention. Makara J Health Res. 2020;24.